iifl-logo-icon 1

Cipla Ltd Share Price

1,506.65
(-0.25%)
Jul 18, 2024|03:32:01 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,497
  • Day's High1,513
  • 52 Wk High1,582
  • Prev. Close1,510.4
  • Day's Low1,485.6
  • 52 Wk Low1,019.5
  • Turnover (lac)32,688.63
  • P/E32.86
  • Face Value2
  • Book Value355.6
  • EPS46
  • Mkt. Cap (Cr.)1,21,664.7
  • Div. Yield0.56
Loading...
  • Open1,510
  • Day's High1,516
  • Spot1,506.65
  • Prev. Close1,514.65
  • Day's Low1,488.9
  • ViewShort BuildUp
  • Market Lot650
  • OI(Chg %)1,64,450 (1.63%)
  • Roll Over%0.29
  • Roll Cost0.75
  • Traded Vol.31,85,000 (42.65%)
View More Futures

Cipla Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,497

Prev. Close

1,510.4

Turnover(Lac.)

32,688.63

Day's High

1,513

Day's Low

1,485.6

52 Week's High

1,582

52 Week's Low

1,019.5

Book Value

355.6

Face Value

2

Mkt Cap (₹ Cr.)

1,21,664.7

P/E

32.86

EPS

46

Divi. Yield

0.56

Cipla Ltd Corporate Action

5 Apr 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

11 May 2023

12:00 AM

Dividend

Dividend Amount: 8.5

Record Date: 21 Jul, 2023

arrow

11 Jul 2023

12:00 AM

AGM

Announcement Date: 11 Jul, 2023

arrow

Cipla Ltd NEWS AND UPDATE

Cipla receives ₹773 Crore demand notice from IT department
18 Jul 2024|10:35 AM

On February 6, 2023, Cipla informed exchanges that I-T department officials had searched some of company offices and manufacturing units.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Cipla Ltd SHAREHOLDING SNAPSHOT

18 Jul, 2024|11:36 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 19.99%

Foreign: 19.99%

Indian: 13.39%

Non-Promoter- 50.14%

Institutions: 50.14%

Non-Institutions: 16.24%

Custodian: 0.21%

Share Price

Cipla Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

161.43

161.36

161.29

161.25

Preference Capital

0

0

0

0

Reserves

24,476.66

22,352.19

19,766.27

17,241.71

Net Worth

24,638.09

22,513.55

19,927.56

17,402.96

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

13,091.79

11,302.71

12,659.15

11,389.9

yoy growth (%)

15.82

-10.71

11.14

5.77

Raw materials

-5,090.24

-4,103.61

-4,319.21

-4,155.49

As % of sales

38.88

36.3

34.11

36.48

Employee costs

-1,729.16

-1,703.58

-1,911.08

-1,785.94

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

3,546.23

2,784

2,964.31

1,988.92

Depreciation

-460.01

-468.62

-599.78

-529.61

Tax paid

-856.84

-739.35

-646.14

-442.88

Working capital

1,126.76

-61.34

1,238.17

865.57

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

15.82

-10.71

11.14

5.77

Op profit growth

9.74

13.3

23.3

37.54

EBIT growth

26.3

-5.7

49.95

63.18

Net profit growth

19.83

6.47

57.85

50.62

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

25,446.63

22,473.18

21,623.36

18,988.52

16,694.85

Excise Duty

0

0

0

0

0

Net Sales

25,446.63

22,473.18

21,623.36

18,988.52

16,694.85

Other Operating Income

327.46

279.94

139.98

171.07

437.14

Other Income

746.57

475.45

280.91

265.99

344.2

Cipla Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,579.3

124.153,78,914.98867.60.855,536.9998.75

Cipla Ltd

CIPLA

1,510.4

32.861,22,044.231,038.40.563,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,570.8

76.931,21,185.085310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,184.8

34.691,19,223.631,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,646.05

25.871,10,827.471,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Cipla Ltd

Management

Register Office

Registrar Office

Chairman (Non-Executive)

Y K Hamied

Vice Chairman

M K Hamied

Non-Exec & Non-Independent Dir

S Radhakrishnan

Non-Exec. & Independent Dir.

Ashok Sinha

Non-Exec. & Independent Dir.

Peter Mugyenyi

Non-Exec. & Independent Dir.

Adil Zainulbhai

Non-Exec. & Independent Dir.

Punita Lal

Executive Vice Chairperson

Samina Hamied

Managing Director & Global CEO

Umang Vohra

Company Sec. & Compli. Officer

Rajendra Chopra

Independent Director

Robert A Stewart

Independent Director

P R Ramesh

Independent Director

Mandar Purushottam Vaidya

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Ciplas product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets. Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. From its first manufacturing unit at Bombay Central in 1936, Cipla now has over 40 state-of-the art manufacturing facilities across the globe including India, USA, China and South Africa.In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company se
Read More

Company FAQs

What is the Cipla Ltd share price today?

Down Arrow

The Cipla Ltd shares price on N/A is Rs.₹1506.05 today.

What is the Market Cap of Cipla Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cipla Ltd is ₹121616.25 Cr. as of 18 Jul ‘24

What is the PE and PB ratio of Cipla Ltd?

Down Arrow

The PE and PB ratios of Cipla Ltd is 32.86 and 4.36 as of 18 Jul ‘24

What is the 52 Week High and Low of Cipla Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Cipla Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Cipla Ltd is ₹1020 and ₹1581.7 as of 18 Jul ‘24

What is the CAGR of Cipla Ltd?

Down Arrow

Cipla Ltd's CAGR for 5 Years at 22.25%, 3 Years at 15.65%, 1 Year at 46.38%, 6 Month at 16.13%, 3 Month at 9.83% and 1 Month at -4.00%.

What is the shareholding pattern of Cipla Ltd?

Down Arrow

The shareholding pattern of Cipla Ltd is as follows:
Promoters - 33.40 %
Institutions - 50.15 %
Public - 16.25 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.